Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece.
Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece.
Gene. 2024 Dec 20;930:148856. doi: 10.1016/j.gene.2024.148856. Epub 2024 Aug 13.
The human NTHL1 gene encodes a DNA glycosylase that plays a key role in the base excision repair (BER) pathway, repairing oxidative DNA damage and maintaining genome integrity. The physiological activity of NTHL1 is crucial in preventing genetic alterations that can lead to cancer. In this study, we employed an innovative targeted DNA sequencing (DNA-seq) methodology to explore the transcriptional landscape of the NTHL1 gene, revealing previously uncharacterized alternative splicing events and novel exons. Our designed approach provided significantly improved sequencing depth and coverage, enabling the identification of novel NTHL1 mRNA transcripts. Bioinformatics analysis confirmed all annotated splice junctions of the main NTHL1 transcripts (v.1 - v.3) and revealed novel mRNA transcripts (NTHL1 v.4 - v.9) derived from splicing events between annotated exons as well as mRNAs containing previously uncharacterized exons (NTHL1 v.10 - v.14). Quantitative PCR analysis highlighted a diverse expression pattern of these novel transcripts across different human cell lines, suggesting cell-specific roles and regulatory mechanisms. Notably, NTHL1 v.5 was overexpressed in luminal A breast cancer cells (MCF-7), while v.13 was prominent in triple negative (BT-20), HER2 + breast cancer (SK-BR-3), prostate, colorectal cancer cells and HEK-293 cells. Our findings suggest that specific novel NTHL1 transcripts may encode protein isoforms with distinct structural features, as indicated by ribosome profiling datasets, while others containing premature termination codons could function as long non-coding RNAs. These insights enhance our understanding of NTHL1 regulatory role and its potential as a biomarker and therapeutic target in human malignancies. This study underscores the importance of exploring the transcriptional diversity of NTHL1 to fully elucidate its role in cancer pathobiology.
人类 NTHL1 基因编码一种 DNA 糖基化酶,在碱基切除修复(BER)途径中发挥关键作用,修复氧化 DNA 损伤并维持基因组完整性。NTHL1 的生理活性对于防止导致癌症的遗传改变至关重要。在这项研究中,我们采用了一种创新的靶向 DNA 测序(DNA-seq)方法来探索 NTHL1 基因的转录景观,揭示了以前未表征的选择性剪接事件和新外显子。我们设计的方法提供了显著提高的测序深度和覆盖度,从而能够鉴定新的 NTHL1 mRNA 转录本。生物信息学分析证实了主要 NTHL1 转录本(v.1-v.3)的所有注释剪接接头,并揭示了源自注释外显子之间剪接事件以及包含以前未表征外显子的 mRNA 的新 mRNA 转录本(NTHL1 v.4-v.9)。定量 PCR 分析突出了这些新转录本在不同人类细胞系中的多样化表达模式,表明存在细胞特异性作用和调节机制。值得注意的是,NTHL1 v.5 在腔 A 型乳腺癌细胞(MCF-7)中过表达,而 v.13 在三阴性(BT-20)、HER2+乳腺癌(SK-BR-3)、前列腺、结直肠癌细胞和 HEK-293 细胞中突出。我们的研究结果表明,特定的新 NTHL1 转录本可能编码具有不同结构特征的蛋白质同工型,如核糖体分析数据集所示,而其他包含提前终止密码子的转录本可能作为长非编码 RNA 发挥作用。这些发现增强了我们对 NTHL1 调节作用及其作为人类恶性肿瘤生物标志物和治疗靶标的潜力的理解。这项研究强调了探索 NTHL1 转录多样性的重要性,以充分阐明其在癌症病理生物学中的作用。